- Lobbying
- Lobbying by Opio Connect, Inc.
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Brian Sutter | Staff Dir. W&M Health subcommittee, Chairman Dave Camp April'13-Dec'14. Professional Staff, W&M Health subcommittee, Chairman Dave Camp, Jan'11-April'13. Leg Dir. Rep Dave Camp, May'08-Jan'11. Leg Asst Rep Dave Camp, Feb'03-May'08. Staff Ast July'02 |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Drug Enforcement Administration (DEA)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Drug Enforcement Administration (DEA)
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Drug Enforcement Administration (DEA)
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Drug Enforcement Administration (DEA)
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Drug Enforcement Administration (DEA)
Type of Issue
Registration
Issue(s) they said they’d lobby about: Issues around modernizing opioid treatment program regulations..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate